Paper37474656
Functional T cell tolerance by peripheral tissue-based checkpoint control.
Carbone FR and 1 other. Nat Immunol, 2023. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Functional T cell tolerance by peripheral tissue-based checkpoint control. Papers, record 37474656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37474656
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| T-Lymphocytes | Major topic |
| Immune Tolerance | Major topic |
| Lymphocyte Activation |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 37344588 | PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens. | https://conductscience.org/library/papers/37344588 |
Source PubMed
References11
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32719479 | Inducible de novo expression of neoantigens in tumor cells and mice. | Nat Biotechnol | 2021 | https://conductscience.org/library/papers/32719479 | PubMed |
| 2 | 31810882 | Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. | Immunity | 2019 | https://conductscience.org/library/papers/31810882 | PubMed |
| 3 | 9670054 | Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. | J Exp Med | 1998 | https://conductscience.org/library/papers/9670054 | PubMed |
| 4 | 37344588 | PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens. | Nature | 2023 | https://conductscience.org/library/papers/37344588 | PubMed |
| 5 | 27411054 | Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. | JAMA Dermatol | 2016 | https://conductscience.org/library/papers/27411054 | PubMed |
| 6 | 29320654 | Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29320654 | PubMed |
| 7 | 29567705 | Cancer immunotherapy using checkpoint blockade. | Science | 2018 | https://conductscience.org/library/papers/29567705 | PubMed |
| 8 | 15780985 | Peripheral tolerance of CD8 T lymphocytes. | Immunity | 2005 | https://conductscience.org/library/papers/15780985 | PubMed |
| 9 | 25769925 | Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade. | J Immunol | 2015 | https://conductscience.org/library/papers/25769925 | PubMed |
| 10 | 25992863 | Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8(+) T Lymphocytes. | Immunity | 2015 | https://conductscience.org/library/papers/25992863 | PubMed |
| 11 | 10535986 | CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. | Proc Natl Acad Sci U S A | 1999 | https://conductscience.org/library/papers/10535986 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40783607 | Real world effectiveness of chemotherapy plus bevacizumab with immunotherapy in colorectal cancer. | Sci Rep | 2025 | https://conductscience.org/library/papers/40783607 | PubMed |
| 40637269 | Bacterial Foreignization Nanosystem Elicits Multi-Phenotypic T Cells for Antitumor Immunity. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40637269 | PubMed |
| 40045029 | Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy. | Curr Treat Options Oncol | 2025 | https://conductscience.org/library/papers/40045029 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37474656
GET https://conductscience.org/api/papers/v1/37474656/authors